SU056 - ≥98% , CAS No.2376580-08-2

CAS: 2376580-08-2 Cat. No.: S651844 Fórmula: C₂₀H₁₆FNO₅ Peso molecular: 369.34

GRADE & PURITY ≥98%

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Visão geral

SU056 is a YB-1 inhibitor. SU056 induces cell-cycle arrest, apoptosis , and inhibits cell migration in ovarian cancer cells. SU056 interacts with YB-1 and inhibits and its associated downstream proteins and pathways. SU056 can enhance the cytotoxic effects of Paclitaxel

In Vitro

SU056 (0-10 μM approximately, 48 h) inhibits cell growth in OVCAR3/4/5/8, SKOV3 and ID8 cells。 SU056 (1 μM, 5-8 days) inhibits colony formation in a dose-dependent manner in OVCAR-8 and ID8 cells。 SU056 (1-5 μM, 6 h) arrests OVCAR8, SKOV3, and ID8 cells in the sub-G1 and G1 phases. SU056 (0-1 μM, 12 h) inhibits cell migration in OVCAR8, SKOV3, and ID8 cells. SU056 (0-5 μM, 24 h) induces apoptotic cell death in OVCAR8, SKOV3, and ID8 cells. SU056 (1-5 μM, 12 h) inhibited the expression of YB-1, TMSB10, SUMO2, and PMSB2 proteins in OVCAR8 cells. SU056 (0.1, 0.5, and 1 μM, 48 h) enhances the cytotoxic effects of Paclitaxel (0.1, 0.5, and 1 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: OVCAR3/4/5/8, SKOV3 and ID8 cells Concentration: 0-10 μM approximately Incubation Time: 48 h Result: Inhibited cell growth with IC 50 values of 1.27, 6.8, 4.33, 3.18, 1.73, 3.75 μM. Cell Migration AssayCell Line: OVCAR8, SKOV3, and ID8 cells Concentration: 0, 0.5, 1 μM Incubation Time: 12 h Result: Dose-dependently inhibited cell migration. Western Blot AnalysisCell Line: OVCAR8 cell Concentration: 1-5 μM Incubation Time: 12 h Result: Dose-dependently inhibited the YB-1, TMSB10, SUMO2, and PMSB2 proteins.

In Vivo

SU056 (20 mg/kg, i.p.) inhibits tumor growth in mice implanted with ID8 cells . SU056 (10 mg/kg, i.p., daily) combined with Paclitaxel (5 mg/kg, weekly, i.p.) shows a much greater reduction in OC tumor growth in immunodeficiency mice implanted with OVCAR8 OC tumors . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 mice implanted (s.c.) with luciferase-expressing ID8 cells Dosage: 20 mg/kg Administration: Intraperitoneal injection (i.p.) Result: Reduced the tumor weight by 2-fold, and is well-tolerated. Reduced the lung metastases. Inhibited YB-1 expression and downstream MDR1 (IHC assay of tumor sample).

Form:Solid

IC50& Target:YB-1

Specifications

Especificações e pureza

≥98%

Mecanismos bioquímicos e fisiológicos

SU056 is a YB-1 inhibitor. SU056 induces cell-cycle arrest, apoptosis , and inhibits cell migration in ovarian cancer cells. SU056 interacts with YB-1 and inhibits and its associated downstream proteins and pathways. SU056 can enhance the cytotoxic effect

Condições de armazenamento de armazenamento

Store at -20°C

Enviado em

Ice chest + Ice pads

Este produto requer transporte de cadeia fria. Serviços terrestres e outros serviços econômicos não estão disponíveis.

Pureza

≥98%

Nomes e identificadores

Sorrisos canónicos

O=C1OCC2=C1C(C3=CC4=C(C=C3N2CCO)OCO4)C5=CC(F)=CC=C5

Peso molecular

369.34

Propriedades químicas e físicas

• Solubilidade: DMSO : 50 mg/mL (135.38 mM; Need ultrasonic)

Perguntas frequentes

What is the purity of this product?

This product is supplied at ≥98% purity (chemical assay). Lot-specific values are stated on the Certificate of Analysis.

How should this product be stored?

Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 2376580-08-2, the molecular formula is C20H16FNO5, and the molecular weight is 369.34 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.